[Elsevier] Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial |
|
This post will be closed automatically in 2026-10-12 22:47
Reward10points
|
post
reply
points
12160
10
Bridging theory and practice: A comprehensive review of virtual power plant technologies and their real-world applications
10
Unravelling the effect of iron doping on ZnS nanoparticles for improved antibacterial, and photocatalytic properties
10
Efficacy of peptide-based enamel coatings in the prevention of demineralization using fixed orthodontic brackets in a rat model
10
Hypoxia alters the upper thermal limits and blood physiology in zebrafish, Danio rerio
10
Electrochemical anodic oxidative fluorination and trifluoroalkylation of organic compounds
